This Crypto Is Set to Explode in December

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Ryan Martins Biography and Net Worth

CFO of 89bio

Ryan Martins serves as Chief Financial Officer of the Company. Prior to joining our company, Mr. Martins was Chief Financial Officer at Revolution Medicines, Inc., from March 2018 to October 2018, where he was responsible for all aspects of the finance function including financial accounting, capital planning, audit, tax and investor relations. Before Revolution Medicines, Mr. Martins was Vice President and Head of Corporate Strategy and Investor Relations at Ultragenyx Pharmaceutical, Inc., from September 2015 to March 2018, where he was responsible for strategic planning, capital raising, investor relations and assisting business development. Prior to Ultragenyx, Mr. Martins spent nearly 10 years as a biotechnology analyst at Jefferies, Lazard, and Barclays/Lehman Brothers after holding operating roles at Chiron Corporation from 2001 to 2006.

What is Ryan Martins' net worth?: The estimated net worth of Ryan Martins is at least $425,409.32 as of April 4th, 2023. Mr. Martins owns 53,578 shares of 89bio stock worth more than $425,409 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Martins may own. Learn More about Ryan Martins' net worth.
How old is Ryan Martins?: Mr. Martins is currently 45 years old. There are 4 older executives and no younger executives at 89bio. The oldest executive at 89bio is Dr. Harry Mansbach M.D., Chief Medical Officer, who is 59 years old. Learn More on Ryan Martins' age.
How do I contact Ryan Martins?: The corporate mailing address for Mr. Martins and other 89bio executives is 142 SANSOME STREET SECOND FLOOR, SAN FRANCISCO CA, 94104. 89bio can also be reached via phone at 415-432-9270 and via email at [email protected]. Learn More on Ryan Martins' contact information.
Has Ryan Martins been buying or selling shares of 89bio?: Ryan Martins has not been actively trading shares of 89bio within the last three months. Most recently, Ryan Martins sold 8,721 shares of the business's stock in a transaction on Tuesday, April 4th. The shares were sold at an average price of $14.95, for a transaction totalling $130,378.95. Following the completion of the sale, the chief financial officer now directly owns 53,578 shares of the company's stock, valued at $800,991.10. Learn More on Ryan Martins' trading history.
Who are 89bio's active insiders?: 89bio's insider roster includes Gregory Grunberg (Director), Ryan Martins (CFO), Rohan Palekar (CEO), Ollin Sykes (Director), and Ram Waisbourd (Insider). Learn More on 89bio's active insiders.
Are insiders buying or selling shares of 89bio?: In the last twelve months, 89bio insiders bought shares 4 times. They purchased a total of 1,375,000 shares worth more than $20,925,450.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 4,477 shares worth more than $48,172.52. The most recent insider tranaction occured on December, 6th when CEO Rohan Palekar bought 5,000 shares worth more than $39,450.00. Insiders at 89bio own 2.8% of the company. Learn More about insider trades at 89bio.
Information on this page was last updated on 12/6/2024.

Ryan Martins Insider Trading History at 89bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/4/2023	Sell	8,721	$14.95	$130,378.95	53,578
3/23/2023	Sell	5,000	$16.11	$80,550.00	53,578
2/21/2023	Sell	2,540	$13.89	$35,280.60	58,578
2/8/2023	Sell	1,480	$14.41	$21,326.80	32,868
2/3/2023	Sell	3,592	$13.04	$46,839.68	35,368
1/3/2023	Sell	5,947	$12.51	$74,396.97	36,368
4/19/2021	Sell	10,000	$25.00	$250,000.00	17,500

Ryan Martins Buying and Selling Activity at 89bio

89bio Company Overview

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Today's Range

Now: $7.94

$6.60

$7.95

50 Day Range

MA: $8.45

$7.03

$10.45

2 Week Range

Now: $7.94

$6.43

$16.63

Volume

4,504,668 shs

Average Volume

980,337 shs

Market Capitalization

$842.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.

Ryan Martins Biography and Net Worth

What is Ryan Martins' net worth?

How old is Ryan Martins?

How do I contact Ryan Martins?

Has Ryan Martins been buying or selling shares of 89bio?

Who are 89bio's active insiders?

Are insiders buying or selling shares of 89bio?